SCHEMBL25075206

SCHEMBL25075206

CC(C)CCOCCOCCN1CCN(C(C)C)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 8/20 0.38
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 2/20 0.36
DAO P14920 1/20 0.36
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 1/20 0.35
MAPK1 P28482 1/20 0.35
KDM1A O60341 1/20 0.35
MAOA P21397 4/20 0.34
HTT P42858 2/20 0.34
HRH3 Q9Y5N1 2/20 0.33
ABCB11 O95342 1/20 0.33
CHRM2 P08172 1/20 0.33
ADRA2A P08913 1/20 0.33
DRD2 P14416 1/20 0.33
ADRA2B P18089 1/20 0.33
ADRA2C P18825 1/20 0.33
DRD4 P21917 1/20 0.33
HRH2 P25021 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19605014 0.98 MAOB (0.39) MAOBALDH1A1KDM4EDAOLMNA
SCHEMBL26445210 0.90 MAOB (0.39) MAOBALDH1A1KDM4EDAOLMNA
SCHEMBL20850751 0.85 KDM4E (0.37) ALDH1A1KDM4EHTTHTR7
SCHEMBL22963141 0.85 KDM4E (0.37) ALDH1A1KDM4EHTTHTR7
SCHEMBL26501022 0.84 PIK3CD (0.39) ALDH1A1KDM4EHTTHRH2HTR7
SCHEMBL23100560 0.84 KDM4E (0.36) ALDH1A1KDM4EHTTHTR2AHTR7
SCHEMBL18270112 0.84 MAOB (0.39) MAOBALDH1A1KDM4EDAOLMNA
SCHEMBL24060966 0.83 ALDH1A1 (0.45) ALDH1A1KDM4EHTTHRH3DRD3
SCHEMBL22791028 0.83 MAOB (0.42) MAOBALDH1A1DAOKDM1AMAOA
SCHEMBL22297559 0.82 MAOB (0.38) MAOBALDH1A1KDM4EDAOLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. 2023-05-04 US disclosed
WO-2023023537-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE ENDOTARGET INC. (US) 2023-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230137175-A1 COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BRUTON'S TYROSINE KINASE BTK, BCL9, CRBN MAOB 1668/4885ALDH1A1 3935/4885KDM4E 551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.